Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome
Launched by MANSOURA UNIVERSITY · Jul 29, 2013
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No more details
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of PCOS based on the revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS (2003).
- • All women were previously treated with 100 mg of CC daily for 5 days per cycle, for two to three cycles with persistent anovulation or ovulate with very thin endometrium \<5 mm at the time of hCG administration
- Exclusion Criteria:
- • patients with hyperprolactinaemia,
- • hypercorticism and
- • thyroid dysfunction.
- • patients receiving medications as cholesterol lowering drugs, as statins, beta-blockers, and tricyclic antidepressants
About Mansoura University
Mansoura University is a prestigious academic institution located in Egypt, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise in various fields of healthcare to facilitate innovative research initiatives aimed at improving patient outcomes. The university collaborates with a network of healthcare professionals and researchers to conduct high-quality clinical trials, focusing on addressing critical health challenges through rigorous scientific methodologies. Its dedication to ethical research practices and adherence to regulatory standards underscores its role as a leader in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mansoura, Dakahlia, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials